Theravance Biopharma (TBPH) to Release Earnings on Monday

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Monday, May 13th. Analysts expect Theravance Biopharma to post earnings of ($0.19) per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. The business had revenue of $17.57 million for the quarter, compared to analyst estimates of $17.49 million. On average, analysts expect Theravance Biopharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Theravance Biopharma Stock Performance

NASDAQ:TBPH traded up $0.14 on Monday, reaching $9.60. The company's stock had a trading volume of 538,900 shares, compared to its average volume of 401,176. Theravance Biopharma has a 1-year low of $8.21 and a 1-year high of $11.98. The business's 50-day moving average price is $9.11 and its two-hundred day moving average price is $9.68. The firm has a market cap of $466.18 million, a PE ratio of -9.90 and a beta of 0.36.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. BTIG Research assumed coverage on Theravance Biopharma in a research note on Friday, April 12th. They set a "buy" rating and a $21.00 target price for the company. Evercore ISI downgraded shares of Theravance Biopharma from an "outperform" rating to an "inline" rating in a research report on Monday, January 8th.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.